Commonwealth Equity Services’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.97M Sell
111,964
-7,119
-6% -$587K 0.01% 943
2025
Q4
$10.2M Sell
119,083
-9,270
-7% -$761K 0.01% 881
2025
Q3
$9.98M Sell
128,353
-4,896
-4% -$383K 0.01% 919
2025
Q2
$10.4M Sell
133,249
-30,752
-19% -$2.29M 0.01% 884
2025
Q1
$11.9M Buy
164,001
+443
+0.3% +$31.7K 0.02% 774
2024
Q4
$12.1M Sell
163,558
-29,569
-15% -$2.07M 0.02% 735
2024
Q3
$12.7M Sell
193,127
-20,494
-10% -$1.49M 0.02% 714
2024
Q2
$19.7M Buy
213,621
+32,358
+18% +$2.87M 0.03% 508
2024
Q1
$17.3M Buy
181,263
+42,744
+31% +$3.59M 0.03% 545
2023
Q4
$10.6M Sell
138,519
-25,465
-16% -$1.77M 0.02% 713
2023
Q3
$11.4M Buy
163,984
+11,117
+7% +$893K 0.02% 626
2023
Q2
$14.4M Buy
152,867
+18,113
+13% +$1.57M 0.03% 538
2023
Q1
$11.1K Buy
134,754
+12,683
+10% +$997K 0.02% 614
2022
Q4
$9.11M Sell
122,071
-16,231
-12% -$1.25M 0.02% 662
2022
Q3
$11.4M Buy
138,302
+2,579
+2% +$248K 0.03% 528
2022
Q2
$12.9M Buy
135,723
+1,396
+1% +$145K 0.03% 478
2022
Q1
$15.8M Buy
134,327
+5,885
+5% +$660K 0.04% 446
2021
Q4
$16.6M Buy
128,442
+45
+0% +$5.25K 0.04% 429
2021
Q3
$14.5M Sell
128,397
-2,020
-2% -$231K 0.04% 436
2021
Q2
$13.5M Buy
130,417
+6,957
+6% +$656K 0.03% 459
2021
Q1
$10.3M Sell
123,460
-4,201
-3% -$355K 0.03% 509
2020
Q4
$11.6M Sell
127,661
-4,328
-3% -$359K 0.04% 433
2020
Q3
$10.5M Sell
131,989
-1,520
-1% -$119K 0.04% 417
2020
Q2
$9.23M Buy
133,509
+20,685
+18% +$1.47M 0.03% 424
2020
Q1
$7.09M Sell
112,824
-14,673
-12% -$1.06M 0.03% 444
2019
Q4
$9.91M Buy
127,497
+3,816
+3% +$298K 0.04% 414
2019
Q3
$9.07M Buy
123,681
+13,566
+12% +$953K 0.04% 411
2019
Q2
$6.78M Buy
110,115
+21
+0% +$1.27K 0.03% 477
2019
Q1
$7.02M Buy
110,094
+25,632
+30% +$1.46M 0.03% 457
2018
Q4
$4.31M Buy
84,462
+4,173
+5% +$211K 0.02% 541
2018
Q3
$4.66M Buy
80,289
+4,005
+5% +$196K 0.02% 558
2018
Q2
$3.7M Sell
76,284
-2,913
-4% -$136K 0.02% 620
2018
Q1
$3.68M Buy
79,197
+8,448
+12% +$367K 0.02% 593
2017
Q4
$2.66M Buy
70,749
+2,133
+3% +$78.3K 0.01% 716
2017
Q3
$2.5M Buy
68,616
+3,351
+5% +$128K 0.02% 698
2017
Q2
$2.57M Buy
65,265
+2,694
+4% +$98.3K 0.02% 656
2017
Q1
$1.96M Buy
62,571
+9,381
+18% +$294K 0.01% 752
2016
Q4
$1.66M Sell
53,190
-54
-0.1% -$1.75K 0.01% 796
2016
Q3
$2.14M Sell
53,244
-6,342
-11% -$239K 0.02% 658
2016
Q2
$1.98M Buy
59,586
+3,021
+5% +$103K 0.02% 654
2016
Q1
$1.66M Sell
56,565
-483
-0.8% -$13.3K 0.01% 714
2015
Q4
$1.5M Buy
57,048
+5,430
+11% +$141K 0.01% 727
2015
Q3
$1.22M Buy
51,618
+4,776
+10% +$115K 0.01% 800
2015
Q2
$1.11M Sell
46,842
-16,812
-26% -$379K 0.01% 897
2015
Q1
$1.51M Buy
63,654
+1,020
+2% +$22.9K 0.02% 730
2014
Q4
$1.33M Buy
62,634
+8,370
+15% +$168K 0.01% 750
2014
Q3
$924K Sell
54,264
-1,290
-2% -$20.4K 0.01% 912
2014
Q2
$795K Buy
55,554
+13,974
+34% +$189K 0.01% 993
2014
Q1
$514K Sell
41,580
-576
-1% -$6.65K 0.01% 1143
2013
Q4
$462K Sell
42,156
-3,450
-8% -$38.9K 0.01% 1174
2013
Q3
$529K Buy
45,606
+3,570
+8% +$41.8K 0.01% 1068
2013
Q2
$471K Buy
+42,036
New +$498K 0.01% 1046

Other funds holding EW

Commonwealth Equity Services's EW Position: Q1 2026 in Review

Commonwealth Equity Services reduced its Edwards Lifesciences (EW) stake by 6% in Q1 2026, selling an estimated $587K and leaving 111,964 shares worth $8.97M. The position accounts for 0.01% of the portfolio, ranked #943.

Commonwealth Equity Services first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.7M in Q2 2024. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Commonwealth Equity Services held 111,964 shares of Edwards Lifesciences worth $8.97M as of Q1 2026.
  • Commonwealth Equity Services sold 7,119 Edwards Lifesciences shares in Q1 2026, an estimated $587K.
  • Edwards Lifesciences made up 0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #943 holding.
  • Commonwealth Equity Services first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Commonwealth Equity Services's Edwards Lifesciences position peaked at $19.7M in Q2 2024.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.